Guest: Jeffrey Stoddard, MD

The age-related decline in immunity is a dominant driver of shingles,1-3 an issue of special concern to older patients. Dr. Jeffrey Stoddard, US Medical Affairs Lead of Zoster Vaccines at GSK, discusses how SHINGRIX addresses this potentially serious health issue. You’ll hear about the vaccine’s high efficacy rates in patients 50 years and older,4 the results of pivotal clinical studies, CDC recommendations, and more.

References:

1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343.
2. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30.
3. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500.
4. Prescribing Information for SHINGRIX.